Alembic Pharma Gets USFDA Nod for Generic Schizophrenia Drug
Alembic Pharmaceuticals receives USFDA approval for its generic version of Paliperidone extended-release tablets, indicated for treating schizophrenia. The drug is therapeutically equivalent to Invega.
New Delhi, Sep 27 (PTI) Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia.
The approval by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Invega extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Pharmaceuticals, Inc, it added.
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for the treatment of schizophrenia and it is also indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilisers and/or antidepressants.
Citing IQVIA data, the company said the Paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg have an estimated market size of USD 48 million for 12 months ended June 2024.
Alembic Pharma said it has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA.
The approval by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Invega extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Pharmaceuticals, Inc, it added.
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for the treatment of schizophrenia and it is also indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilisers and/or antidepressants.
Citing IQVIA data, the company said the Paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg have an estimated market size of USD 48 million for 12 months ended June 2024.
Alembic Pharma said it has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 6.96 ( -1.69)
- 32087619
- Spicejet Ltd.
- 45.48 ( -6.38)
- 24487576
- Srestha Finvest
- 0.56 (+ 3.70)
- 15767473
- G G Engineering
- 1.00 ( 0.00)
- 13488004
- YES Bank Ltd.
- 16.20 (+ 0.31)
- 11982994
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback